{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:15:52Z","timestamp":1787980552843,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T00:00:00Z","timestamp":1679097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T00:00:00Z","timestamp":1679097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40263-023-00995-9","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T01:24:42Z","timestamp":1679880282000},"page":"363-370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0789-7765","authenticated-orcid":false,"given":"Simon","family":"Fung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Shirley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,18]]},"reference":[{"issue":"12","key":"995_CR1","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","volume":"17","author":"SJ Pittock","year":"2021","unstructured":"Pittock SJ, Zekeridou A, Weinshenker BG. Hope for patients with neuromyelitis optica spectrum disorders\u2014from mechanisms to trials. Nat Rev Neurol. 2021;17(12):759\u201373.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"995_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","volume":"261","author":"C Trebst","year":"2014","unstructured":"Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261(1):1\u201316.","journal-title":"J Neurol"},{"issue":"2","key":"995_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40265-018-1039-7","volume":"79","author":"N Collongues","year":"2019","unstructured":"Collongues N, Ayme-Dietrich E, Monassier L, et al. Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options. Drugs. 2019;79(2):125\u201342.","journal-title":"Drugs"},{"issue":"2","key":"995_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177\u201389.","journal-title":"Neurology"},{"issue":"10","key":"995_CR5","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.1007\/s00415-022-11241-5","volume":"269","author":"F Costello","year":"2022","unstructured":"Costello F, Burton JM. Contemporary management challenges in seropositive NMOSD. J Neurol. 2022;269(10):5674\u201381.","journal-title":"J Neurol"},{"issue":"1","key":"995_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40259-020-00460-9","volume":"35","author":"C Valencia-Sanchez","year":"2021","unstructured":"Valencia-Sanchez C, Wingerchuk DM. Emerging targeted therapies for neuromyelitis optica spectrum disorders. BioDrugs. 2021;35(1):7\u201317.","journal-title":"BioDrugs"},{"issue":"2","key":"995_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/biomedicines7020042","volume":"7","author":"MA Lana-Peixoto","year":"2019","unstructured":"Lana-Peixoto MA, Talim N. Neuromyelitis optica spectrum disorder and anti-MOG syndromes. Biomedicines. 2019;7(2):42.","journal-title":"Biomedicines."},{"issue":"5","key":"995_CR8","doi-asserted-by":"publisher","first-page":"e841","DOI":"10.1212\/NXI.0000000000000841","volume":"7","author":"K Fujihara","year":"2020","unstructured":"Fujihara K, Bennett JL, de Seze J, et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e841.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"12","key":"995_CR9","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1007\/s00415-009-5274-4","volume":"256","author":"A Uzawa","year":"2009","unstructured":"Uzawa A, Mori M, Ito M, et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol. 2009;256(12):2082\u20134.","journal-title":"J Neurol"},{"issue":"1","key":"995_CR10","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000311","volume":"4","author":"Y Takeshita","year":"2017","unstructured":"Takeshita Y, Obermeier B, Cotleur AC, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2017;4(1): e311.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"12","key":"995_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083036","volume":"8","author":"N Chihara","year":"2013","unstructured":"Chihara N, Aranami T, Oki S, et al. Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica. PLoS ONE. 2013;8(12): e83036.","journal-title":"PLoS ONE"},{"issue":"3","key":"995_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","volume":"70","author":"I Ayzenberg","year":"2013","unstructured":"Ayzenberg I, Kleiter I, Schroder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 2013;70(3):394\u20137.","journal-title":"JAMA Neurol"},{"key":"995_CR13","unstructured":"Roche Registration GmbH. Enspryng 120 mg solution for injection in pre-filled syringe. 2021. https:\/\/www.ema.europa.eu\/. Accessed 13 Feb 2023."},{"key":"995_CR14","unstructured":"Roche Registration GmbH. Enspryng\u00ae 120 mg solution, for subcutaneous use 2022. https:\/\/dailymed.nlm.nih.gov\/. Accessed 13 Feb 2023."},{"issue":"15 Suppl.","key":"995_CR15","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1212\/WNL.94.15_supplement.1483","volume":"94","author":"S Lennon-Chrimes","year":"2020","unstructured":"Lennon-Chrimes S, Baumann HS, Klingelschmitt G, et al. Characterisation of the PK and PD of satralizumab, a recycling antibody, to support Q4W dosing in patients with NMOSD [abstract no. 1483]. Neurology. 2020;94(15 Suppl.):1483.","journal-title":"Neurology"},{"issue":"15 Suppl.","key":"995_CR16","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1212\/WNL.94.15_supplement.1492","volume":"94","author":"C Hemingway","year":"2020","unstructured":"Hemingway C, Baumann HS, Kou XJ, et al. Adolescents with NMOSD achieved similar exposures and favorable safety profile when treated with the adult satralizumab dosing regimen [abstract no. 1492]. Neurology. 2020;94(15 Suppl.):1492.","journal-title":"Neurology"},{"issue":"22","key":"995_CR17","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114\u201324.","journal-title":"N Engl J Med"},{"issue":"5","key":"995_CR18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402\u201312.","journal-title":"Lancet Neurol"},{"issue":"10","key":"995_CR19","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485\u20139.","journal-title":"Neurology"},{"issue":"1","key":"995_CR20","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200071","volume":"10","author":"I Kleiter","year":"2023","unstructured":"Kleiter I, Traboulsee A, Palace J, et al. Long-term efficacy of satralizumab in AQP4-IgG\u2013seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2023;10(1): e200071.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"995_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104025","volume":"66","author":"T Yamamura","year":"2022","unstructured":"Yamamura T, Weinshenker B, Yeaman MR, et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022;66: 104025.","journal-title":"Mult Scler Relat Disord."},{"issue":"15 Suppl.","key":"995_CR22","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1212\/WNL.96.15_supplement.4118","volume":"96","author":"A Traboulsee","year":"2021","unstructured":"Traboulsee A, Yeaman MR, Weinshenker BG, et al. Satralizumab in patients with neuromyelitis optica spectrum disorder and concomitant autoimmune disease [abstract no. 4118]. Neurology. 2021;96(15 Suppl.):4118.","journal-title":"Neurology"},{"key":"995_CR23","unstructured":"Alexion Pharmaceuticals. Soliris 300 mg concentrate for solution for infusion. 2021. https:\/\/www.ema.europa.eu\/. Accessed 13 Feb 2023."},{"key":"995_CR24","unstructured":"Horizon Therapeutics. Uplizna 100 mg concentrate for solution for infusion. 2022. https:\/\/www.ema.europa.eu\/. Accessed 13 Feb 2023."},{"issue":"1 Suppl.","key":"995_CR25","first-page":"20","volume":"28","author":"JL Bennett","year":"2022","unstructured":"Bennett JL, Fox E, Greenberg B, et al. Long-term efficacy and safety of satralizumab in adults with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD): results from the phase 3 SAkura studies [abstract no. P277]. Mult Scler J. 2022;28(1 Suppl.):20\u2013214.","journal-title":"Mult Scler J."},{"issue":"1","key":"995_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","volume":"20","author":"M Levy","year":"2021","unstructured":"Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021;20(1):60\u20137.","journal-title":"Lancet Neurol"},{"issue":"7","key":"995_CR27","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40265-020-01297-w","volume":"80","author":"JE Frampton","year":"2020","unstructured":"Frampton JE. Eculizumab: a review in neuromyelitis optica spectrum disorder. Drugs. 2020;80(7):719\u201327.","journal-title":"Drugs"},{"key":"995_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00949-7","author":"T Nie","year":"2022","unstructured":"Nie T, Blair HA. Inebilizumab: a review in neuromyelitis optica spectrum disorder. CNS Drugs. 2022. https:\/\/doi.org\/10.1007\/s40263-022-00949-7.","journal-title":"CNS Drugs"},{"issue":"18 Suppl.","key":"995_CR29","first-page":"P15-1.002","volume":"98","author":"A Traboulsee","year":"2022","unstructured":"Traboulsee A, Fujihara K, Kim HJ, et al. SAkuraBONSAI: a prospective, open-label study of satralizumab investigating novel imaging, biomarker, and clinical outcomes in patients with aquaporin-4-IgG-seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) [abstract no. P15-1.002]. Neurology. 2022;98(18 Suppl.):P15-1.002.","journal-title":"Neurology"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-00995-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-00995-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-00995-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T17:19:31Z","timestamp":1702142371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-00995-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,18]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["995"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-00995-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,18]]},"assertion":[{"value":"16 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Simon Fung and Matt Shirley are salaried employees of Adis International Ltd\/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}